Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

PLX

Protalix BioTherapeutics Inc

Nov 19 • 04:00PM ET

1.77

-0.11 -5.85 %

Healthcare • Biotechnology • USA • AMEX

Peers: SRPT BMRN ALNY FOLD ARWR BLUE QURE EDIT ABEO DTIL

Scroll to Statements

Index	RUT	P/E	25.47	EPS (ttm)	0.07	Insider Own	10.58%	Shs Outstand	80.34M	Perf Week	-17.29%
Market Cap	142.35M	Forward P/E	3.25	EPS next Y	0.55	Insider Trans	1.54%	Shs Float	71.91M	Perf Month	-17.29%
Enterprise Value	121.16M	PEG	-	EPS next Q	0.04	Inst Own	18.09%	Short Float	5.78%	Perf Quarter	12.03%
Income	5.39M	P/S	2.30	EPS this Y	225.00%	Inst Trans	3.06%	Short Ratio	5.09	Perf Half Y	3.51%
Sales	61.84M	P/B	2.69	EPS next Y	319.23%	ROA	7.50%	Short Interest	4.16M	Perf YTD	-5.85%
Book/sh	0.66	P/C	4.85	EPS next 5Y	-	ROE	12.64%	52W High	3.10 -42.90%	Perf Year	26.43%
Cash/sh	0.37	P/FCF	-	EPS past 3/5Y	- -	ROIC	9.04%	52W Low	1.32 34.09%	Perf 3Y	65.42%
Dividend Est.	-	EV/EBITDA	15.57	Sales past 3/5Y	11.67% -0.48%	Gross Margin	57.54%	Volatility	9.05% 6.90%	Perf 5Y	-47.94%
Dividend TTM	-	EV/Sales	1.96	EPS Y/Y TTM	153.26%	Oper. Margin	10.30%	ATR (14)	0.15	Perf 10Y	-82.12%
Dividend Ex-Date	-	Quick Ratio	2.06	Sales Y/Y TTM	35.42%	Profit Margin	8.72%	RSI (14)	32.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.03	EPS Q/Q	-13.39%	SMA20	-18.81%	Beta	-0.18	Target Price	14.00
Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	-0.60%	SMA50	-18.81%	Rel Volume	0.59	Prev Close	1.88
Employees	213	LT Debt/Eq	0.13	Earnings	Nov 13 BMO	SMA200	-12.68%	Avg Volume	816.36K	Price	1.77
IPO	Apr 09, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-45.45% -0.19%	Trades		Volume	487,769	Change	-5.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$3 → $11
Apr-17-17	Reiterated	Rodman & Renshaw	Buy	$4 → $5
Apr-04-16	Initiated	Rodman & Renshaw	Buy	$3.50
Apr-23-15	Upgrade	Jefferies	Hold → Buy	$2 → $2.60
Nov-12-14	Reiterated	R. F. Lafferty	Buy	$8 → $5
Jan-24-14	Initiated	R. F. Lafferty	Buy	$8
May-02-12	Reiterated	Oppenheimer	Outperform	$9 → $11
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $8
Apr-30-12	Downgrade	Auriga	Buy → Hold	$8 → $8
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy	$10
Nov-09-10	Reiterated	Oppenheimer	Outperform	$10 → $12
Oct-14-10	Reiterated	UBS	Buy	$9 → $10.75
Dec-02-09	Reiterated	Hapoalim	Outperform	$10 → $12
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform	$10
Dec-01-08	Reiterated	Oppenheimer	Outperform	$6 → $4
Mar-11-08	Initiated	UBS	Buy	$6
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform	$7

Show Previous Ratings

Nov-13-25 02:05PM	Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com) -9.81%
06:55AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results (PR Newswire)
Nov-06-25 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 (PR Newswire) -6.72%
Sep-29-25 06:50PM	Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase (Insider Monkey)
10:55AM	Loading…
Sep-11-25 10:55AM	Protalix BioTherapeutics to Present at Investor Summit Virtual (ACCESSWIRE)
Sep-02-25 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire) +5.81%
Aug-14-25 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results (PR Newswire) -5.59%
Aug-07-25 12:53PM	Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 (PR Newswire)
Jul-21-25 06:50AM	Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer (PR Newswire)
Jul-18-25 06:57AM	Fabry Disease Treatment Analysis Report 2025 \| Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth (GlobeNewswire)
Jun-30-25 06:50AM	Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes (PR Newswire)
May-14-25 06:50AM	Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC (PR Newswire)
May-10-25 03:04AM	Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
May-09-25 07:02AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -40.48%
06:50AM	Loading…
06:50AM	Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results (PR Newswire)
May-05-25 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 (PR Newswire) -5.33%
Apr-10-25 09:54AM	Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline (Seeking Alpha)
Mar-24-25 06:50AM	Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 (PR Newswire)
Mar-22-25 05:42PM	Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE) +5.51%
Mar-18-25 03:01AM	Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Mar-17-25 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results (PR Newswire) +9.38%
Mar-10-25 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 (PR Newswire)
Feb-04-25 06:50AM	Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference (PR Newswire)
Dec-23-24 06:50AM	Protalix BioTherapeutics Issues 2025 Letter to Stockholders (PR Newswire)
Dec-10-24 10:35AM	EMA validates Chiesi and Protalixs dose variation for Fabry disease (Pharmaceutical Technology)
Dec-09-24 06:30AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa (PR Newswire)
Nov-15-24 02:10AM	Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-14-24 07:03AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance) +13.71%
06:50AM	Loading…
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results (PR Newswire)
Nov-07-24 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 (PR Newswire)
Oct-25-24 07:18AM	Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 (PR Newswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
08:35AM	Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 (GlobeNewswire)
Sep-04-24 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.61%
Sep-03-24 06:50AM	Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes (PR Newswire) +13.32%
Aug-30-24 08:38AM	Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-14-24 06:57AM	Protalix: Q2 Earnings Snapshot (Associated Press Finance) -10.58%
06:50AM	Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results (PR Newswire)
Aug-07-24 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 (PR Newswire)
Jun-13-24 06:50AM	Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout (PR Newswire)
May-29-24 08:38AM	Protalix BioTherapeutics to Present at the 2024 BIO International Convention (PR Newswire)
May-13-24 03:05AM	Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-11-24 10:27AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 06:56AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -12.00%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results (PR Newswire)
May-03-24 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 (PR Newswire)
Mar-15-24 01:17PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 08:11AM	Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023 (GuruFocus.com) -9.87%
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results (PR Newswire)
Mar-07-24 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 (PR Newswire)
Feb-23-24 06:50AM	Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference (PR Newswire)
Dec-26-23 06:50AM	Protalix BioTherapeutics Issues 2024 Letter to Stockholders (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire) +5.59%
Nov-07-23 09:04AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:04AM	Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results (GuruFocus.com) -18.38%
06:58AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results (PR Newswire)
Oct-30-23 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 (PR Newswire)
Oct-09-23 06:50AM	Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel (PR Newswire) -6.71%
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-06-23 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-08-23 09:14AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	PLX: Second Quarter Results (Zacks)
Aug-07-23 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results (PR Newswire) +14.46%
Aug-01-23 06:50AM	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-31-23 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 (PR Newswire)
Jun-08-23 06:50AM	Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease (PR Newswire)
May-30-23 11:00AM	PLX: Back of the Envelope (Zacks Small Cap Research)
06:50AM	Protalix BioTherapeutics Issues Letter to Stockholders (PR Newswire)
May-23-23 06:50AM	Protalix BioTherapeutics set to join Russell 3000® Index (PR Newswire) +7.55%
May-18-23 06:50AM	Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases (PR Newswire) -9.32%
May-11-23 07:59AM	PLX: FDA Approval of Elfabrio (Zacks Small Cap Research) -13.27%
May-10-23 04:16PM	Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics (Benzinga)
06:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com) -7.03%
May-05-23 07:26AM	PLX: One Down, One to Go (Zacks Small Cap Research)
06:46AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease (PR Newswire)
May-04-23 06:50AM	Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results (PR Newswire) +6.67%
Apr-27-23 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023 (PR Newswire)
Mar-21-23 06:50AM	Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout (PR Newswire)
Mar-13-23 06:50AM	Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank (PR Newswire)
Feb-28-23 08:52PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
04:32AM	PLX: May is a Big Month (Zacks Small Cap Research)
Feb-27-23 06:30AM	Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results (PR Newswire)
Feb-24-23 09:15AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease (PR Newswire) +7.06%
Feb-21-23 06:55AM	Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium 2023 (PR Newswire)
06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023 (PR Newswire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research) +6.99%
Jan-03-23 06:50AM	Protalix BioTherapeutics Issues 2023 Letter to Stockholders (PR Newswire)
Dec-21-22 04:30PM	Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange (PR Newswire) -7.81%
Dec-05-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease (PR Newswire) +5.31%
Dec-04-22 09:00AM	Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102 (PR Newswire)
Nov-30-22 02:59PM	Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment (News Direct)
Nov-15-22 04:46AM	PLX: BLA Submitted: 1H:23 Responses (Zacks Small Cap Research)
Nov-14-22 06:50AM	Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results (PR Newswire)
06:30AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease (PR Newswire)
Nov-07-22 06:50AM	Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 (PR Newswire)

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bar-Shalev Amos	Director	Nov 18 '25	Sale	1.87	168	314	0	Nov 19 04:34 PM
Schwartz Aharon	Director	Jun 10 '25	Buy	1.60	129,000	205,884	303,000	Aug 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

PLX

Protalix BioTherapeutics Inc

Upgrade your FINVIZ experience